Courtagen Life Sciences Announced Today the Launch of New Tests for Epilepsy and Mitochondrial Disorders

Courtagen launched today the epiSEEK® Focus and nucSEEK® Focus clinical genetic tests

WOBURN, Mass.--()--Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of several new Next Generation Sequencing tests focused on expanding diagnostic options for physicians treating patients suffering from epilepsy and seizure disorders, and mitochondrial disease.

Courtagen added the nucSEEK® Focus Nuclear Mitochondrial Gene Panel and epiSEEK® Focus Epilepsy and Seizure Disorder Panel to the company’s test offerings. The new tests will complement the current nucSEEK® Comprehensive Nuclear Mitochondrial Exome Panel and epiSEEK® Comprehensive Epilepsy and Seizure Disorder Panel, respectively. Physicians will now have more flexibility to choose the most appropriate test for their patient.

“Our new nucSEEK® Focus and epiSEEK® Focus panels are good examples of Courtagen’s ability to respond to physician’s feedback and provide the types of genetic tests they want,” said Brian McKernan, Chief Executive Officer of Courtagen. “Our deep experience with Next Generation Sequencing, coupled with our streamlined laboratory and bioinformatics operations, allows us to rapidly develop and deliver high-quality tests for genetic analysis and clinical interpretation.”

The nucSEEK® Focus panel includes 181 genes associated with mitochondrial disorders. This is a complex set of diseases that can have a range of indications, including developmental delays, autism spectrum disorders, seizures, migraines, chronic fatigue, complex regional pain syndrome, and involuntary nervous system dysfunction (including cyclic vomiting syndrome and heart muscle disease). The epiSEEK® Focus panel includes 76 genes associated with epilepsy and seizure disorders, including early and adult on-set disease types.

About Courtagen Life Sciences, Inc.

Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.

Contacts

Courtagen Life Sciences, Inc.
Mike Catalano, 877-395-7608
mike.catalano@courtagen.com

Release Summary

Courtagen Life Sciences Announced Today the Launch of New Tests for Epilepsy and Mitochondrial Disorders

Contacts

Courtagen Life Sciences, Inc.
Mike Catalano, 877-395-7608
mike.catalano@courtagen.com